50 new drugs received FDA approval in 2024

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023 . Last year’s number of drug approvals is similar to what the agency achieved in other years in the 2020s, with the exception of 2022 , when it approved just 37. The 28 small-molecule therapies approved last year account for 56% of new drugs, the same percentage of new small-molecule therapies approved in 2023. Antibody-based drugs were also plentiful; 13 of them were approved, which represents 26% of 2024’s new molecular entities, up from 22% in 2023. C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that are approved by the FDA’s Center for Biologics Evaluation and Research . Among 2024’s notable new drugs were three approvals for antibiotic therapies: Allecra Therapeutics’